Halozyme Therapeutics, Inc. (HALO) 2026 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good afternoon. My name is Joel and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's third-quarter 2026 financial and operating results conference call.

    下午好。我叫 Joel,今天將擔任本次電話會議的接線員。此刻,我謹代表公司歡迎各位參加 Halozyme 2026 年第三季財務與營運成果電話會議。

  • (Operator Instructions) Please note: This event is being recorded.

    (接線員指示) 請注意:本活動將被錄音。

  • I will now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations. Please go ahead.

    接下來我將把電話交給 Halozyme 投資人關係副總裁 Tram Bui。請開始。

  • Tram Bui - Vice President - Investor Relations, Corporate Communications

    Tram Bui - Vice President - Investor Relations, Corporate Communications

  • Thank you, operator. Good afternoon and welcome to Halozyme's third-quarter 2026 financial and operating results conference call.

    謝謝,接線員。下午好,歡迎各位參加 Halozyme 2026 年第三季財務與營運成果電話會議。

  • In addition to the press release issued today, after the market close, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.

    除了今天在收盤後發布的新聞稿之外,您也可以在我們網站的投資人關係專區找到一份補充簡報投影片;我們將在今天的電話會議中引用該簡報。

  • Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Darren Snellgrove, our Chief Financial Officer, who will review our financial results and outlook.

    本次電話會議由 Halozyme 總裁兼執行長 Helen Torley 博士主講,將提供公司業務最新進展;以及我們的財務長 Darren Snellgrove,將回顧財務結果與展望。

  • On today's call, we will be making forward-looking statements, as outlined on slide 2. I would also refer you to our SEC filings for a full list of risks and uncertainties.

    在今天的電話會議中,我們將做出前瞻性陳述,如投影片第 2 頁所述。我也請各位參閱我們向 SEC 提交的文件,以取得完整的風險與不確定性清單。

  • During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.

    在本次電話會議中,我們將同時討論 GAAP 與非 GAAP 財務衡量指標。部分非 GAAP 或調整後財務衡量指標,已在我們的財報新聞稿與投影片簡報中,與相對應的 GAAP 財務衡量指標進行調節。

  • I will now turn the call over to Dr. Helen Torley. And we will start on slide 3.

    接下來我將把電話交給 Helen Torley 博士。我們將從投影片第 3 頁開始。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Thank you, Tram. And, good afternoon, everyone.

    謝謝你,Tram。各位下午好。

  • I am pleased to report another exceptionally strong quarter for Halozyme, as more patients, physicians, and healthcare systems experience the benefits of subcutaneous delivery with ENHANZE. This is reflected in the record total and Royalty Revenues.

    我很高興向各位報告,Halozyme 再次交出極為強勁的一季表現;隨著更多病患、醫師與醫療體系體驗到 ENHANZE 皮下注射給藥的效益,這也反映在創新高的總營收與權利金收入上。

  • And, operationally, we continue to demonstrate new growth opportunities, resulting from our compounding platform engine, ENHANZE.

    在營運方面,我們也持續展現新的成長機會,這些機會源自我們的複合平台引擎 ENHANZE。

  • In and post the quarter, we significantly expanded the ENHANZE opportunity, with three current partners expanding their agreements to add four new target nominations.

    在本季期間及季後,我們大幅擴大 ENHANZE 的機會版圖;三家現有合作夥伴擴增其協議,新增四項新的標的提名。

  • Additionally, three ENHANZE-enabled programs, one each from Pfizer, Incyte, and Argenx, advanced into Phase 1 development.

    此外,三個採用 ENHANZE 的計畫(分別來自 Pfizer、Incyte 與 Argenx)已推進至第一期臨床開發。

  • And GSK plans to initiate a Phase 1b study of a subcutaneous formulation of belantamab with ENHANZE. With this planned start, we are on track to achieve 13 ENHANZE programs in clinical development by year end.

    另外,GSK 計畫啟動一項使用 ENHANZE 的 belantamab 皮下劑型第一期 b 試驗。隨著此項計畫啟動,我們可望在年底前達成 13 個處於臨床開發階段的 ENHANZE 計畫。

  • Importantly, we also advanced our two hyper-concentration technologies, Hypercon and Aerocon, the new name for Surf Bio, moving these closer to clinical testing.

    同樣重要的是,我們也推進兩項高濃度化技術 Hypercon 與 Aerocon(Surf Bio 的新名稱),使其更接近進入臨床測試。

  • All of this contributed to the record total revenue, Royalty Revenue, and adjusted EBITDA for Q3.

    上述各項進展共同促成第三季創新高的總營收、權利金收入與調整後 EBITDA。

  • Total revenue increased 39% year over year to $493 million, driven by Royalty Revenue, which increased 44% to a record $341 million. These results reflect the continued growth of our established commercial-partner product portfolio and the growing contributions from the newer launches, which is resulting in a diversified and growing set of Royalty Revenue streams.

    總營收年增 39% 至 4.93 億美元,主要由權利金收入帶動;權利金收入年增 44% 至創新高的 3.41 億美元。這些結果反映我們既有商業合作夥伴產品組合的持續成長,以及較新上市產品貢獻的增加,進而形成多元且成長中的權利金收入來源組合。

  • Profitability remained strong during the quarter, with adjusted EBITDA of $336 million and an adjusted EBITDA margin of 68%, reflecting our disciplined execution.

    本季獲利能力維持強勁,調整後 EBITDA 為 3.36 億美元,調整後 EBITDA 利潤率為 68%,反映我們嚴謹且有紀律的執行。

  • Based on this strength, we are raising our full-year 2026 financial guidance. Darren will be discussing this in greater detail.

    基於這樣的強勁表現,我們上調 2026 全年財務指引。Darren 將就此進一步詳細說明。

  • Turning to slide 4, let me now say a few more words about how we are increasing the ENHANZE opportunity through expanded agreements and new nominations by current partners.

    接著看投影片第 4 頁,我想再多談幾句,說明我們如何透過擴增協議以及現有合作夥伴的新提名,來提升 ENHANZE 的機會。

  • Three current ENHANZE partners expanded their Collaborations and nominated four additional targets.

    三家現有 ENHANZE 合作夥伴擴大其合作關係,並額外提名四個標的。

  • Argenx expanded their agreement to include two additional exclusive targets, bringing the total to eight. Incyte expanded and added one additional target to evaluate subcutaneous axatilimab. And, in October, Johnson & Johnson added an additional oncology target to its longstanding ENHANZE Collaboration.

    Argenx 擴增其協議,新增兩個額外的獨家標的,使總數達到八個。Incyte 擴增合作並新增一個標的,以評估 axatilimab 的皮下劑型。此外在 10 月,Johnson & Johnson 在其長期 ENHANZE 合作中新增一個腫瘤學標的。

  • Collectively, these four new nominations expand the opportunity, further diversify our partnered pipeline, and add new potential sources of Milestone and Royalty Revenue.

    整體而言,這四項新提名擴大了機會、進一步分散我們的合作管線,並新增潛在的里程碑金與權利金收入來源。

  • Let me now move to slide 5 and I'll provide some performance highlights on our commercial ENHANZE portfolio:

    接下來到投影片第 5 頁,我將分享我們商業化 ENHANZE 產品組合的一些表現重點:

  • DARZALEX SUBCUTANEOUS, VYVGART HYTRULO, and PHESGO have all continued to demonstrate strong Royalty Revenue growth. In addition to and on top of this, OCREVUS ZUNOVO, OPDIVO QVANTIG, and RYBREVANT FASPRO are adding increasingly meaningful Royalty Revenues.

    DARZALEX SUBCUTANEOUS、VYVGART HYTRULO 與 PHESGO 的權利金收入皆持續展現強勁成長。此外,在此基礎之上,OCREVUS ZUNOVO、OPDIVO QVANTIG 與 RYBREVANT FASPRO 也正帶來愈來愈具意義的權利金收入。

  • ENHANZE provides a competitive advantage for our partners by improving convenience, reducing administration time, and, in some cases, improving the safety and tolerability profile compared to the IV treatment.

    ENHANZE 透過提升便利性、縮短給藥時間,並在某些情況下相較於靜脈注射(IV)治療改善安全性與耐受性概況,為合作夥伴提供競爭優勢。

  • For multiple partner products, these benefits are resulting in strong growth, as the SC enables new sites of care and increase access to and for patients.

    對於多項合作夥伴產品而言,這些效益正帶動強勁成長,因為皮下給藥(SC)使新的照護場域成為可能,並提升病患的可近性與可獲得性。

  • I'll begin with highlights on the newer launch products:

    我先從較新上市產品的亮點開始:

  • Roche continues to report strong momentum for subcutaneous OCREVUS ZUNOVO, with approximately 56,000 patients globally now receiving the 10-minute subcutaneous formulation, an increase of about 12,000 patients since the first half of the year.

    Roche 持續回報皮下 OCREVUS ZUNOVO 的強勁動能;目前全球約有 56,000 名病患正在使用 10 分鐘皮下劑型,較上半年增加約 12,000 名病患。

  • Global conversion from OCREVUS IV to subcutaneous has now exceeded 20%, with adoption driven by both conversion and, importantly, new patients starting on OCREVUS ZUNOVO.

    全球從 OCREVUS 靜脈注射(IV)轉換至皮下劑型的比例現已超過 20%;採用動能同時來自既有病患轉換,更重要的是,來自新病患開始使用 OCREVUS ZUNOVO。

  • Roche noted on their third-quarter call that approximately 50% of the OCREVUS ZUNOVO starts are patients naïve to OCREVUS treatment. This, I believe, demonstrates expansion of OCREVUS ZUNOVO into community and more rural treatment settings, where IV capacity can be limited.

    Roche 在其第三季電話會議中指出,約 50% 的 OCREVUS ZUNOVO 起始用藥者為先前未接受過 OCREVUS 治療的病患。我認為這顯示 OCREVUS ZUNOVO 正擴展至社區與較偏鄉的治療場域,而這些地方的靜脈注射容量可能受限。

  • Roche continues to expect high-single-digit OCREVUS growth in 2026 and CHF9 billion or approximately $11 billion in peak franchise sales by 2029. At just over 20% conversion to date and with Royalty Revenues to, at least, 2034, this represents a large opportunity for Halozyme.

    Roche 仍預期 2026 年 OCREVUS 將維持高個位數成長,並在 2029 年達到 90 億瑞士法郎(CHF),或約 110 億美元的高峰產品線銷售額。以目前略高於 20% 的轉換率,以及至少可延續至 2034 年的權利金收入來看,這對 Halozyme 而言代表龐大的機會。

  • I'll move now to Bristol Myers Squibb and OPDIVO QVANTIG. On its third-quarter call, BMS reported that approximately 17% of the OPDIVO IV business has already converted to OPDIVO QVANTIG, which is the subcutaneous formulation, with uptake occurring across multiple tumor types.

    接著談 Bristol Myers Squibb 與 OPDIVO QVANTIG。BMS 在其第三季電話會議中表示,約有 17% 的 OPDIVO 靜脈注射(IV)業務已轉換為皮下劑型 OPDIVO QVANTIG,且在多種腫瘤類型中皆有採用。

  • Importantly, they also commented that conversion is tracking towards the higher end of its expectation for 30% to 40% of the IV business to ultimately convert to the subcutaneous formulation.

    更重要的是,他們也提到,轉換進度正朝向其預期區間的較高端發展,也就是最終將有 30% 至 40% 的 IV 業務轉換為皮下劑型。

  • SC administration with ENHANZE is delivering meaningful benefits for patients and physicians, including improved practice efficiency and a more convenient treatment experience.

    採用 ENHANZE 的皮下(SC)給藥,正為病患與醫師帶來顯著效益,包括提升診所作業效率與更便利的治療體驗。

  • With durable royalties projected for many years and significant conversion ahead, this also represents an attractive growth royalty stream.

    在可望維持多年的長期權利金,以及仍有顯著轉換空間的情況下,這也代表一條具吸引力的成長型權利金收入來源。

  • Johnson & Johnson's RYBREVANT FASPRO is another exciting opportunity. J&J reported 63.5% growth of RYBREVANT plus LAZCLUZE in the third quarter, driven by strong share gains in both first- and second-line lung cancer treatment, continued launch uptake across regions, and rapid adoption of the subcutaneous version, RYBREVANT FASPRO.

    Johnson & Johnson 的 RYBREVANT FASPRO 是另一個令人振奮的機會。J&J 報告第三季 RYBREVANT 加上 LAZCLUZE 成長 63.5%,主要受惠於在第一線與第二線肺癌治療中市占率強勁提升、各地區上市導入持續推進,以及皮下版本 RYBREVANT FASPRO 的快速採用。

  • They further noted that they expect FDA approval of RYBREVANT FASPRO in advanced head and neck cancer by the end of 2026, which would expand the opportunity beyond lung cancer into another area of significant unmet need.

    他們進一步指出,預期 RYBREVANT FASPRO 將於 2026 年底前在晚期頭頸癌取得 FDA 核准,這將把機會從肺癌擴展到另一個存在重大未被滿足醫療需求的領域。

  • Johnson & Johnson also highlighted that RYBREVANT is one of their key newer products that is expected to contribute more meaningfully to future growth and have commented that this growth will be fueled by RYBREVANT FASPRO.

    嬌生(Johnson & Johnson)亦強調,RYBREVANT 是其關鍵的新產品之一,預期將對未來成長做出更具意義的貢獻,並表示此成長將由 RYBREVANT FASPRO 所驅動。

  • This represents another growth Royalty Revenue stream for Halozyme, with Royalty Revenues projected to the late 2030s.

    這為 Halozyme 帶來另一條權利金收入(Royalty Revenue)成長來源,權利金收入預計可延續至 2030 年代末。

  • I'll now move to DARZALEX SUBCUTANEOUS, VYVGART HYTRULO, and PHESGO. I'll begin with DARZALEX.

    接下來我將談 DARZALEX SUBCUTANEOUS、VYVGART HYTRULO 與 PHESGO。我先從 DARZALEX 開始。

  • J&J reported $4.2 billion in sales in the third quarter for DARZALEX, reflecting operational growth of 15.6%. Virtually all of the DARZALEX reported sales are for the DARZALEX SUBCUTANEOUS version with ENHANZE.

    J&J 報告 DARZALEX 第三季銷售額為 42 億美元,反映營運成長 15.6%。幾乎所有 DARZALEX 的申報銷售額皆來自搭配 ENHANZE 的 DARZALEX SUBCUTANEOUS 版本。

  • This strong performance was driven by continued share gains across all lines of therapy, including 10 points of share gain in the front-line setting, together with ongoing market expansion.

    此一強勁表現主要由各治療線別的市占持續提升所帶動,包括在一線治療情境中市占提升 10 個百分點,並伴隨市場持續擴張。

  • With analysts now projecting sales of $21 billion in 2028, we are excited to support the continued growth and expansion of this exceptional product.

    隨著分析師目前預估 2028 年銷售額可達 210 億美元,我們很高興能支持這項卓越產品的持續成長與擴張。

  • I'll move now to VYVGART HYTRULO. Argenx reported total VYVGART sales of $1.7 billion in the quarter, impressive growth of 54% year over year and 13% sequentially.

    接著談 VYVGART HYTRULO。Argenx 報告本季 VYVGART 總銷售額為 17 億美元,年增 54%、季增 13%,成長亮眼。

  • Argenx highlighted continued growth in both generalized myasthenia gravis and CIDP, which is driven by the VYVGART HYTRULO pre-filled syringe that provides greater patient convenience and flexibility in how treatment is administered.

    Argenx 強調在全身型重症肌無力與 CIDP 兩個適應症皆持續成長,主要由 VYVGART HYTRULO 預充式注射器所驅動,該產品為病患提供更高的便利性與在治療給藥方式上的彈性。

  • A recent additional driver of growth is the approval for seronegative myasthenia gravis, which is already broadening their prescriber base, with approximately 10% of seronegative prescribers new to VYVGART.

    近期另一項成長動能來自血清陰性重症肌無力的核准,已開始擴大其開立處方醫師基礎;約有 10% 的血清陰性處方醫師為 VYVGART 的新使用者。

  • Further opportunity expansion is projected in 2027, with potential approvals in ocular and pediatric myasthenia gravis.

    預計在 2027 年將有進一步的機會擴張,可能在眼肌型與兒科重症肌無力取得核准。

  • And, beyond myasthenia gravis and CIDP, Argenx is seeking to expand into a new population of patients, those with immune-mediated necrotizing [myositis], or IMNM, with a sBLA planned by year end. This is a high-unmet-need patient population, where Argenx has estimated there are approximately 20,000 patients living with this disease in the United States alone.

    此外,除重症肌無力與 CIDP 之外,Argenx 正尋求擴展至新的病患族群,即免疫介導壞死性[肌炎](immune-mediated necrotizing [myositis]),或 IMNM,並計畫於年底前提交 sBLA。這是一個高度未被滿足醫療需求的病患族群,Argenx 估計僅在美國就約有 20,000 名患者罹患此疾病。

  • These opportunities reinforce the potential for VYVGART HYTRULO to continue expanding across indications, patient populations, and prescribers, delivering long-term growth and projected Royalty Revenues to Halozyme into the 2040s.

    這些機會進一步強化 VYVGART HYTRULO 在適應症、病患族群與處方醫師面向持續擴張的潛力,帶來長期成長,並為 Halozyme 帶來預計可延續至 2040 年代的權利金收入。

  • Moving now to Roche's PHESGO, in the third quarter, Roche reported that PHESGO also continued to deliver strong performance, with global conversion reaching 59%, up 5 percentage points since mid-year, signaling continued strong adoption for a product that was launched six years ago in 2020.

    接著談羅氏(Roche)的 PHESGO。第三季羅氏報告 PHESGO 亦持續展現強勁表現,全球轉換率達 59%,較年中提高 5 個百分點,顯示這項於 2020 年、六年前上市的產品仍持續被強力採用。

  • The continued conversion from PERJETA reinforces the durability of PHESGO, with royalties projected into the 2030s; and the value of ENHANZE in enabling sustained adoption of subcutaneous therapies.

    持續自 PERJETA 的轉換進一步印證 PHESGO 的持久性,權利金預計可延續至 2030 年代;同時也凸顯 ENHANZE 在促成皮下療法持續採用方面的價值。

  • Collectively, all six products are demonstrating the continued scalability and durability of ENHANZE. Our established products continue to deliver strong growth. Our newer launches are becoming increasingly meaningful contributors. And the ongoing clinical, regulatory, and commercial progress are providing multiple drivers for future revenue growth.

    綜合而言,六項產品皆展現 ENHANZE 持續可擴展性與持久性。我們既有產品持續帶來強勁成長。我們較新的上市產品正成為愈來愈重要的貢獻來源。而持續的臨床、法規與商業進展,正提供多重未來營收成長動能。

  • Moving now to slide 6, with the new study starts in the third quarter, we have significantly expanded our product-development pipeline.

    接著看第 6 張投影片,隨著第三季新增研究啟動,我們已大幅擴充產品開發管線。

  • To date, we have 12 ENHANZE programs in clinical development; three of which the partners have requested to keep confidential at this time. With GSK planning to initiate a Phase 1b study of a subcutaneous formulation of belantamab with ENHANZE, we are on track to reach 13 clinical-stage programs by year-end 2026.

    截至目前,我們有 12 項 ENHANZE 計畫處於臨床開發階段;其中 3 項合作夥伴目前要求保密。隨著 GSK 計畫啟動一項搭配 ENHANZE 的 belantamab 皮下劑型第 1b 期研究,我們正按計畫於 2026 年底前達到 13 項臨床階段計畫。

  • Recent advancements to highlight are Pfizer's initiation of a Phase 1 study of tilrekimig, their investigational, potential first-in-class trispecific antibody that simultaneously inhibits upstream and downstream drivers of type 2 inflammation; also, Incyte's initiation of a Phase 1 study, evaluating a subcutaneous formulation of their first-in-class antibody, designed to selectively target mutant calreticulin; and, finally, Argenx's evaluation of ARGX-119, their first-in-class humanized, agonist, monoclonal antibody targeting MuSK.

    近期值得強調的進展包括:輝瑞(Pfizer)啟動 tilrekimig 的第 1 期研究,該藥為其研發中、可能為同類首創(first-in-class)的三特異性抗體,可同時抑制第 2 型發炎的上游與下游驅動因子;此外,Incyte 啟動第 1 期研究,評估其同類首創抗體的皮下劑型,該抗體旨在選擇性鎖定突變型鈣網蛋白(calreticulin);最後,Argenx 正評估 ARGX-119,為其同類首創的人源化、致效型(agonist)單株抗體,靶向 MuSK。

  • Importantly, multiple partners are moving programs from Collaboration signing into the clinic rapidly within months of signing. This momentum is a strong reflection of a broader trend in biopharmaceutical companies, focusing on subcutaneous administration.

    重要的是,多家合作夥伴在簽署合作協議後,於數月內便迅速將計畫推進至臨床階段。此一動能強烈反映生物製藥公司更廣泛的趨勢:聚焦於皮下給藥。

  • Subcutaneous delivery is now recognized not simply as a convenience feature but as an important driver of patient preference, healthcare-system efficiency, competitive differentiation, and market expansion.

    皮下給藥如今不再僅被視為便利性功能,而是驅動病患偏好、醫療體系效率、競爭差異化與市場擴張的重要因素。

  • This pace of execution, combined with attractive opportunities across oncology, immunologies, and multiple other therapeutic areas, represents a highly attractive set of opportunities for ENHANZE Royalty Revenue beginning in the 2029-plus period and extending well into the next decade.

    此一執行速度,加上在腫瘤、免疫學及其他多個治療領域的具吸引力機會,構成一組對 ENHANZE 權利金收入極具吸引力的機會,預計自 2029 年以後期間開始,並延伸至下一個十年深處。

  • This is the compounding platform engine at work: commercial success driving new partner demand, new agreements creating additional development programs, and those programs building the next waves of potential Royalty Revenue.

    這正是複利平台引擎(compounding platform engine)在運作:商業成功帶動新的合作夥伴需求,新協議創造更多開發計畫,而這些計畫建立下一波潛在的權利金收入。

  • An important additional benefit of our compounding platform engine is the continuous innovation that is generated, as we work with partners across a growing range of molecules, formulations, and delivery challenges.

    我們複利平台引擎的另一項重要額外效益,是在與合作夥伴共同面對日益多元的分子、配方與遞送挑戰時,所持續產生的創新。

  • I am pleased to report that Collaboration patents have been obtained by our Licensees for 7 of the 10 launch products and that Collaboration patents are pending for the others.

    我很高興報告,10 項已上市產品中有 7 項之被授權方(Licensees)已取得合作專利(Collaboration patents),其餘產品的合作專利亦在申請審查中。

  • We continue to expect that new Collaboration patents will be granted to protect our Licensees' innovations, as they generate new data from their clinical trials.

    我們仍預期,隨著被授權方從其臨床試驗產出新數據,將有新的合作專利獲准,以保護其創新成果。

  • Let me now move to MDASE and our modified-hyaluronidase IP portfolio. Halozyme pioneered and invented the use of hyaluronidases for large-volume subcutaneous delivery.

    接下來我將談 MDASE 與我們的改造型透明質酸酶(modified-hyaluronidase)智慧財產權(IP)組合。Halozyme 開創並發明了將透明質酸酶用於大容量皮下遞送的用途。

  • On October 7, 2026, the specialized [Dutch Patent Court] of The Hague rejected Merck's invalidity challenges against Halozyme's MDASE patent, EP622, and found KEYTRUDA QLEX to be infringing the patent.

    2026 年 10 月 7 日,海牙的專門[荷蘭專利法院]駁回默克(Merck)對 Halozyme 之 MDASE 專利 EP622 提出的無效挑戰,並認定 KEYTRUDA QLEX 侵害該專利。

  • The court also found that there was no reasonable likelihood that EP622 will be declared invalid in the other relevant European member states where EP622 is granted and prohibited Merck's European-marketing approval holder from committing an infringement in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands by manufacturing or causing to be manufactured, offering, putting on the market, or using KEYTRUDA SUBCUTANEOUS in those countries; or by importing it or holding it in stock for that purpose.

    法院亦認定,在 EP622 已獲授權的其他相關歐洲成員國中,EP622 被宣告無效的合理可能性不高,並禁止默克的歐洲上市許可持有人在比利時、丹麥、法國、愛爾蘭、義大利、瑞典、瑞士與荷蘭透過製造或促使製造、要約、投放市場或使用 KEYTRUDA SUBCUTANEOUS,或為該目的進口或囤貨,而構成侵權。

  • Previously, in December of 2025, Halozyme won a critical preliminary injunction in Germany for EP622. The [Munich Regional Court] ordered Merck to halt the launch and distribution of KEYTRUDA QLEX in Germany.

    此前於 2025 年 12 月,Halozyme 在德國就 EP622 贏得關鍵的初步禁制令。[慕尼黑地方法院]命令默克停止在德國推出與銷售 KEYTRUDA QLEX。

  • And, in February of 2026, the German Federal Patent Court issued a preliminary opinion in validity proceedings that were brought by Merck, finding that Halozyme's EP622 patent is likely valid.

    並且在 2026 年 2 月,德國聯邦專利法院在默克提起的有效性程序中發布初步意見,認定 Halozyme 的 EP622 專利很可能有效。

  • Together, these rulings prevent Merck from launching KEYTRUDA QLEX in key European markets and prevent Merck from achieving the same adoption and trajectory of KEYTRUDA QLEX in Europe, as they are doing in the United States.

    綜合而言,這些裁決阻止默克在歐洲主要市場推出 KEYTRUDA QLEX,並使默克無法在歐洲達成其在美國所呈現的 KEYTRUDA QLEX 相同採用程度與發展軌跡。

  • I want to underscore just how important these recent EU court decisions are in supporting the validity of our EP622 patent and supporting Halozyme's position as the pioneer and leader for innovating the use of human-derived hyaluronidases for large-volume subcutaneous administration.

    我想強調,近期歐盟法院的這些裁決在支持我們 EP622 專利的有效性,以及支持 Halozyme 作為以人源透明質酸酶創新用於大容量皮下給藥之先驅與領導者的立場方面,是多麼重要。

  • I'll now move to Hypercon and Aerocon, our hyper-concentration technologies. Hypercon and Aerocon are complementary technologies to ENHANZE that extend our leadership in subcutaneous drug delivery, expand our addressable opportunity, and will create additional long-term royalty opportunities for Halozyme.

    接下來我將談到我們的 Hypercon 與 Aerocon 超高濃度技術。Hypercon 與 Aerocon 是 ENHANZE 的互補技術,可延伸我們在皮下藥物遞送領域的領導地位、擴大我們可觸及的機會,並將為 Halozyme 創造額外的長期權利金機會。

  • Each has been demonstrated to achieve stable formulations of biologic therapies at a concentration of approximately 500 milligrams per mL, which is three to fourfold what is commonly achieved.

    兩者皆已證實可在約每毫升 500 毫克的濃度下,達成生物製劑療法的穩定配方,約為一般常見可達成濃度的三到四倍。

  • The resultant lower volume required can allow delivery, using a small-volume auto-injector, at home or in the doctor's office, with the potential to further improve the patient-treatment experience.

    因此所需體積更低,可在家中或醫師診間使用小容量自動注射器進行給藥,並有望進一步改善病患的治療體驗。

  • To date, five Collaboration and licensing agreements have been signed for access to Hypercon, including the potential to use Hypercon with more than 20 potential targets or drugs.

    截至目前,我們已簽署五項合作與授權協議以取得 Hypercon 的使用權,其中包括可將 Hypercon 應用於超過 20 個潛在標的或藥物的可能性。

  • We are on track to complete the clinical supply for two partner products formulated with Hypercon in the first quarter of 2027 to support first-half 2027 Phase 1 trial initiations.

    我們正按計畫於 2027 年第一季完成兩項合作夥伴產品(採用 Hypercon 配方)的臨床供應,以支援 2027 年上半年啟動第一期試驗。

  • In parallel, we're advancing the Hypercon formulation for a growing portfolio of development programs, including both commercial-stage and development-stage assets, with several programs originating from recently signed Collaborations and others representing future Collaboration-agreement opportunities.

    同時,我們也在推進 Hypercon 配方,用於日益擴大的開發計畫組合,其中包含商業化階段與開發階段資產;多個計畫源自近期簽署的合作案,另有一些則代表未來合作協議的機會。

  • Now, a word on Aerocon: We're on track with our plans for 2026, which continue to support new deal signings in 2027 and clinical entry in the second half of 2028.

    接著簡要談 Aerocon:我們 2026 年的計畫進展順利,持續支援於 2027 年簽署新交易,並於 2028 年下半年進入臨床階段。

  • With Halozyme's deep expertise, established capabilities, and proven track record in drug delivery, Halozyme is the natural home for innovative drug-delivery technologies.

    憑藉 Halozyme 深厚的專業能力、既有的能力建置,以及在藥物遞送方面經驗證的實績,Halozyme 是創新藥物遞送技術的理想歸屬。

  • I'll now pass the call over to Darren, who will be discussing our financial results, updated outlook, and capital allocation.

    接下來我把電話交給 Darren,他將說明我們的財務結果、更新後的展望,以及資本配置。

  • Darren Snellgrove - Chief Financial Officer

    Darren Snellgrove - Chief Financial Officer

  • Thank you, Helen. I will start on slide 7.

    謝謝你,Helen。我將從第 7 張投影片開始。

  • The third quarter was another exceptional quarter for Halozyme. We delivered record royalty and total revenue, strong earnings growth, and substantial cash flow generation, while continuing to advance our future growth opportunities.

    第三季對 Halozyme 而言又是極為出色的一季。我們創下權利金與總營收的新高,獲利強勁成長,並產生可觀的現金流,同時持續推進我們未來的成長機會。

  • Our results reflect the increasing diversification of our royalty portfolio, with continued outperformance of our established commercial products and growing contributions from newer launches.

    我們的結果反映出權利金組合日益多元化:既有商業化產品持續優於預期,新上市產品的貢獻也在增加。

  • Combined with the ongoing advancement and expansion of our pipeline, this supports the long-term durability of our revenue.

    再加上我們研發管線持續推進與擴充,這些因素共同支撐我們營收的長期韌性。

  • We also successfully completed a $1.5 billion convertible note offering on attractive terms. The transaction reflects the strength of our financial profile and confidence in our long-term outlook, while further strengthening our balance sheet.

    我們也以具吸引力的條件成功完成 15 億美元可轉換公司債發行。此交易反映我們財務體質的強勁與對長期展望的信心,同時進一步強化資產負債表。

  • Turning to the third -quarter results, total revenue increased 39% to $493 million compared to $354.3 million in the prior-year period. This performance was driven by robust Royalty Revenue growth and higher Product Sales.

    回到第三季業績,總營收較去年同期的 3.543 億美元成長 39%,達到 4.93 億美元。此表現主要由權利金收入的強勁成長以及產品銷售增加所帶動。

  • Moving to slide 8 for more details on Royalty Revenue, Royalty Revenue increased 44% year over year to a record $341 million, reflecting continued strength across our commercial portfolio.

    接著看第 8 張投影片,了解權利金收入的更多細節:權利金收入年增 44% 至創紀錄的 3.41 億美元,反映我們商業化產品組合整體持續強勁。

  • Third-quarter DARZALEX Royalty Revenue increased 20% year over year to $153.5 million. VYVGART royalties to Halozyme increased 89% year over year to $88.1 million. PHESGO Royalty Revenue increased 23% year over year to $34.3 million in the third quarter.

    第三季 DARZALEX 權利金收入年增 20% 至 1.535 億美元。VYVGART 支付給 Halozyme 的權利金年增 89% 至 8,810 萬美元。PHESGO 權利金收入在第三季年增 23% 至 3,430 萬美元。

  • Other Royalty Revenue increased 92% to $65.1 million, driven by growing contributions from OCREVUS Zunovo, OPDIVO QVANTIG, RYBREVANT FASPRO, and TECENTRIQ HYBREZA.

    其他權利金收入成長 92% 至 6,510 萬美元,主要由 OCREVUS Zunovo、OPDIVO QVANTIG、RYBREVANT FASPRO 與 TECENTRIQ HYBREZA 的貢獻增加所帶動。

  • Moving to slide 9 for additional details on profitability and our balance sheet, research and development expenses were $27.8 million compared to $17.3 million in the prior-year period, reflecting continued investment in advancing our ENHANZE and next-generation technology platforms.

    接著看第 9 張投影片,了解獲利能力與資產負債表的更多細節:研發費用為 2,780 萬美元,去年同期為 1,730 萬美元,反映我們持續投資以推進 ENHANZE 與下一代技術平台。

  • Selling, general, and administrative expenses were $58.2 million in the quarter compared to $46.1 million in the prior-year period. The increase in SG&A expenses was primarily due to an increase in consulting fees, including litigation costs related to Merck.

    本季銷售、一般及行政費用為 5,820 萬美元,去年同期為 4,610 萬美元。SG&A 費用增加主要是因顧問費用上升,其中包括與默克相關的訴訟成本。

  • Net income increased 41% to $247 million from $175.2 million in the prior-year period.

    淨利年增 41%,由去年同期的 1.752 億美元增至 2.47 億美元。

  • Adjusted EBITDA increased 35% to $336.2 million from $248.2 million in the prior-year period, driven by continued strong royalty growth.

    調整後 EBITDA 年增 35%,由去年同期的 2.482 億美元增至 3.362 億美元,主要受持續強勁的權利金成長所帶動。

  • GAAP diluted earnings per share was $2.01 compared to $1.43 in the prior-year period. And non-GAAP diluted earnings per share was $2.39 compared to $1.72 in the third quarter of 2025.

    依 GAAP 計算的稀釋後每股盈餘為 2.01 美元,去年同期為 1.43 美元。非 GAAP 稀釋後每股盈餘為 2.39 美元,2025 年第三季為 1.72 美元。

  • Moving to slide 10, our capital-allocation priorities are unchanged. We remain focused on investing in the highest-return opportunities across ENHANZE, Hypercon, and Aerocon, maintaining a strong balance sheet, and returning excess capital to shareholders through a disciplined capital-return framework.

    接著看第 10 張投影片,我們的資本配置優先順序維持不變。我們仍專注於投資 ENHANZE、Hypercon 與 Aerocon 中報酬最高的機會,維持強健的資產負債表,並透過嚴謹的資本回饋架構將多餘資本回饋給股東。

  • Consistent with this approach, we completed $400 million of share repurchases in 2026.

    依循此一方針,我們在 2026 年完成了 4 億美元的庫藏股回購。

  • We also remain focused on deleveraging, including addressing our 2027 and 2028 convertible notes at maturity. Our net leverage was 2.4 times.

    我們也持續專注於去槓桿,包括在到期時處理我們 2027 年與 2028 年的可轉換公司債。我們的淨槓桿倍數為 2.4 倍。

  • We ended the quarter with $1.08 billion in cash, cash equivalents, and marketable securities; and $3.3 billion of long-term debt, leaving us well-positioned to fund our organic growth initiatives, while maintaining significant financial flexibility.

    本季末我們持有 10.8 億美元的現金、約當現金與有價證券;以及 33 億美元的長期負債,使我們在資助內生成長計畫的同時,仍能維持顯著的財務彈性。

  • Beyond our organic investments, we will continue to evaluate selective strategic opportunities that complement our portfolio and meet our discipline criteria for strategic fit, durable value creation, and attractive returns.

    除內生投資外,我們也將持續評估具選擇性的策略機會,以補強我們的產品組合,並符合我們在策略契合度、可持續的價值創造與具吸引力報酬方面的紀律標準。

  • Moving to slide 11, based on our performance through the first nine months, we are raising our 2026 financial guidance.

    接著看第 11 張投影片,基於我們前九個月的表現,我們上調 2026 年財務指引。

  • We now expect total revenue of $1.86 billion to $1.925 billion, an increase of $20 million at the midpoint, representing growth of 33% to 38% over 2025.

    我們目前預期總營收為 18.6 億至 19.25 億美元,中位數上調 2,000 萬美元,較 2025 年成長 33% 至 38%。

  • Within that, we now expect Royalty Revenue of $1.235 billion to $1.255 billion, up $12.5 million at the midpoint, representing growth of 42% to 45%. Royalties remain the engine of our business and the main driver of this raise.

    其中,我們目前預期權利金收入為 12.35 億至 12.55 億美元,中位數上調 1,250 萬美元,代表成長 42% 至 45%。權利金仍是我們業務的引擎,也是本次上調的主要驅動因素。

  • We now expect Product Sales of $525 million to $540 million, up $7.5 million at the midpoint.

    我們目前預期產品銷售為 5.25 億至 5.40 億美元,中位數上調 750 萬美元。

  • We are raising adjusted EBITDA to $1.24 billion to $1.29 billion, up $12.5 million at the midpoint, with our adjusted EBITDA margin unchanged at approximately 67%.

    我們將調整後 EBITDA 上調至 12.4 億至 12.9 億美元,中位數上調 1,250 萬美元;調整後 EBITDA 利潤率維持不變,約為 67%。

  • Finally, we now expect non-GAAP diluted EPS of $8.75 to $9.05, up $0.08 at the midpoint.

    最後,我們目前預期非 GAAP 稀釋後每股盈餘為 8.75 至 9.05 美元,中位數上調 0.08 美元。

  • The updated outlook reflects the continued strength of our diversified royalty portfolio, substantial operating leverage, and strong cash generation.

    更新後的展望反映我們多元化權利金組合的持續強勁、可觀的營運槓桿,以及強勁的現金創造能力。

  • With that, I'll turn the call back to Helen.

    接下來我把電話交回給 Helen。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Thank you, Darren.

    謝謝你,Darren。

  • In closing, our third-quarter performance demonstrates the strength of our compounding technology platform, ENHANZE, where the actions during and post this quarter added meaningful near- and long-term value.

    最後總結,我們第三季的表現展現了我們複利式技術平台 ENHANZE 的實力;本季期間及季後所採取的行動,為公司在短期與長期都增添了具意義的價值。

  • Hypercon and Aerocon share many similar features and will create two additional compounding platforms, on top of ENHANZE.

    Hypercon 與 Aerocon 具有許多相似特性,並將在 ENHANZE 之上,再打造兩個額外的複利式平台。

  • Let me leave you with four key take-aways:

    最後,我想留給各位四個關鍵重點:

  • Firstly, our royalty portfolio continues to grow and diversify. Record Royalty Revenue and growing contributions from three more recently launched products demonstrate the increasing breadth and durability of our business.

    第一,我們的權利金投資組合持續成長並更加多元化。權利金營收創新高,以及另外三項較近期上市產品的貢獻持續增加,展現我們業務版圖日益擴大且具備長期韌性。

  • Secondly, demand for ENHANZE remains exceptionally strong. The expanded agreements with existing partners will add multiple new programs into the development portfolio, with the potential to broaden the reach of ENHANZE and create new Royalty Revenue streams.

    第二,ENHANZE 的需求依然異常強勁。與既有合作夥伴擴大協議,將把多個新專案納入開發組合,有望擴大 ENHANZE 的觸及範圍並創造新的權利金營收來源。

  • Thirdly, we're growing the next wave of royalty opportunities. We're on track to add 13 ENHANZE programs in clinical development by year end.

    第三,我們正在培育下一波權利金機會。我們按計畫在年底前,將臨床開發中的 ENHANZE 專案增加至 13 項。

  • Hypercon also remains on track for its first clinical-trial start in the first half of 2027.

    Hypercon 也仍按計畫在 2027 年上半年啟動其首項臨床試驗。

  • And, finally, our strong cash generation and financial flexibility provide additional capacity to invest in our technologies, while maintaining a disciplined approach to capital allocation.

    最後,我們強勁的現金創造能力與財務彈性,讓我們在維持嚴謹資本配置紀律的同時,也具備額外能力投資於我們的技術。

  • Each new royalty stream, future launch opportunity, and partnership adds another layer of growth, on top of the foundation we have already built.

    每一條新的權利金來源、未來的上市機會與合作夥伴關係,都在我們既有基礎之上再疊加一層成長動能。

  • I thank you all for your time today. And, operator, you can now open the call for questions.

    感謝各位今天撥冗參與。接線員,現在可以開放提問。

  • Operator

    Operator

  • We will now begin the question-and-answer session.

    我們現在開始問答環節。

  • (Operator Instructions)

    (接線員指示)

  • Jason Butler, Citizens JMP.

    Jason Butler,Citizens JMP。

  • Jason Butler - Analyst

    Jason Butler - Analyst

  • Hi. Thanks for taking the questions. And congrats on the quarter.

    嗨,感謝開放提問。也恭喜本季表現。

  • Helen, now that you're several quarters past the last two acquisitions, what do you think your capacity is to bring in more synergistic technologies? And what's your perspective on priority there?

    Helen,距離最近兩次收購已過了好幾個季度,你認為公司還有多大能力再引進更多具協同效益的技術?你對於這方面的優先順序有何看法?

  • And then, I have a follow-up. Thanks.

    另外我還有一個追問。謝謝。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. If it's okay, Jason, I'll ask Darren to address that.

    好的。如果可以的話,Jason,我請 Darren 來回答。

  • Darren Snellgrove - Chief Financial Officer

    Darren Snellgrove - Chief Financial Officer

  • Yeah. Thanks for the question, Jason.

    好的,謝謝你的問題,Jason。

  • So, for M&A, what I'd say is that, our two recent acquisitions, Hypercon and Aerocon, are progressing well. And so those are important growth drivers for us to continue to invest behind.

    關於併購(M&A),我想說的是,我們最近兩項收購 Hypercon 與 Aerocon 進展良好。因此,這些都是我們持續投入的重要成長驅動因素。

  • And the good news is both our organic opportunities and our financial position are strong so that really gives us the patience to be disciplined, as it relates to M&A; and act, really, only when we can find a deal that can clearly improve the long-term outlook.

    好消息是,我們的內生成長機會與財務狀況都很強健,這讓我們在併購上能夠有耐心並保持紀律;只有在找到能明確改善長期展望的交易時,才會採取行動。

  • So we would expect a new deal to really be something that would expand the drug-delivery portfolio, something that could extend our royalty duration or strengthen the long-term revenue outlook. And, obviously, it needs to meet the appropriate return threshold.

    因此,我們預期新的交易應該能擴大藥物遞送產品組合、延長權利金年限或強化長期營收展望。當然,也必須符合適當的報酬門檻。

  • So we're definitely interested in technology that complements our platforms that can be deployed through scalable partnerships. And so that is really what we are looking for.

    所以,我們確實對能補強我們平台、並可透過可擴展的合作夥伴關係加以部署的技術感興趣。這就是我們真正尋找的方向。

  • Jason Butler - Analyst

    Jason Butler - Analyst

  • Great. Thank you.

    很好。謝謝你。

  • And then, in terms of the hyper-concentration technologies, when you are speaking to prospective partners, what are they looking for, in terms of technical proof of concept, to move forward with a program? And when do you think we will have the initial data from established partnerships that could provide that initial proof of concept?

    另外,關於超高濃度(hyper-concentration)技術,當你們與潛在合作夥伴洽談時,他們在技術概念驗證方面通常希望看到什麼,才會推進一個專案?你認為我們何時能從既有合作關係取得初步數據,以提供最初的概念驗證?

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. I think there are two elements of proof of concept, Jason, to think about:

    是的,Jason,我認為概念驗證可以從兩個面向來看:

  • One is the actual formulation. Can you formulate the product into a hyper-concentrated product? As you know, we have got multiple examples and very successful examples of doing that, up to 500 milligrams per ml.

    第一是實際的配方。你能否把產品配製成超高濃度的產品?如你所知,我們已有多個案例,而且非常成功,濃度可達每毫升 500 毫克。

  • What we are finding is, for some companies, they want to see it first; and, other companies, they will accept the fact it is going to be very possible, based on the wealth of data we already have. So I think that is one.

    我們發現,有些公司希望先親眼看到;而另一些公司則會基於我們既有的大量數據,接受這件事高度可行。所以我認為這是一個面向。

  • And, on the call, I mentioned we have got multiple people in feasibility testing. Some of them are partners who signed before. The early-development testing does encompass that formulation testing.

    另外,我在電話會議中提到,我們有多個對象正在進行可行性測試。其中一些是先前已簽約的合作夥伴。早期開發測試確實包含這類配方測試。

  • Some of that is our current partners and some of it is people who want to get that data before they move forward to a new agreement.

    其中一部分來自我們現有合作夥伴,另一部分則是希望在推進新協議前先取得數據的公司。

  • So we actually have a little bit of a pipeline of potential future agreements in that group of companies who are testing the formulation.

    因此,在這群正在測試配方的公司中,我們其實形成了一條潛在未來協議的小型管線。

  • I think the next proof of concept is the clinical proof of concept. The companies that are most advanced and we expect to be in the clinic in the first half of 2027 have done the pre-clinical data. They have done all of that testing they can do.

    我認為下一個概念驗證是臨床概念驗證。目前進度最超前、且我們預期在 2027 年上半年進入臨床的公司,已完成臨床前數據。他們已完成所有能做的測試。

  • The next real step that they want to see is the clinical data. And so we are excited to be supporting them and moving forward to these Phase 1 studies that will evaluate [PK], local tolerability, things like that.

    他們接下來真正想看到的是臨床數據。因此,我們很期待能支持他們,推進這些第一期研究,以評估 [PK]、局部耐受性等項目。

  • So those would be the two things but everything is advancing exactly as we had expected. And we are looking forward to starting the clinical studies in 2027.

    所以大致就是這兩點;而且一切進展都完全符合我們的預期。我們也期待在 2027 年啟動臨床研究。

  • Jason Butler - Analyst

    Jason Butler - Analyst

  • Great. Thanks for taking the question.

    很好。謝謝回答我的問題。

  • Operator

    Operator

  • Michael DiFiore, Evercore ISI.

    Michael DiFiore,Evercore ISI。

  • Michael DiFiore - Analyst

    Michael DiFiore - Analyst

  • Hey, guys. Thanks so much for taking my question. And congrats on all the continued progress.

    嗨,各位。非常感謝讓我提問。也恭喜你們持續取得各項進展。

  • Another question from me on Hypercon: Helen, what's the most important assumptions driving the $1 billion Hypercon royalty opportunity? And how much of that opportunity depends on established molecules just undergoing a formulation bridge versus investigational molecules that still need to demonstrate efficacy?

    我還有一個關於 Hypercon 的問題:Helen,推動 Hypercon 權利金機會達到 10 億美元的最重要假設是什麼?而這個機會中,有多少取決於既有分子僅需進行配方橋接(formulation bridge),相較於仍需證明療效的研發中分子?

  • Thank you.

    謝謝。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. As we put out that projection that we can achieve $1 billion, we were looking at an expectation of having five to seven products that would be in the clinic before the mid-2030s for that, Mike.

    是的。當我們提出可達成 10 億美元的預測時,Mike,我們的假設是:在 2030 年代中期之前,會有 5 到 7 項產品進入臨床。

  • And that does include -- majority of those products already are clinically de-risked in terms of already-being-launched products. But there are some exciting earlier-stage products that we do anticipate have the potential to launch by that time, as well.

    其中確實包含——多數產品在臨床風險上已大幅降低,因為它們是已上市產品。但也有一些令人振奮的較早期產品,我們也預期它們有潛力在那之前上市。

  • But a heavy skew to already-successful commercial products.

    但整體上明顯偏向已在商業上成功的產品。

  • Michael DiFiore - Analyst

    Michael DiFiore - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Mitchell Kapoor, HC Wainwright.

    Mitchell Kapoor,HC Wainwright。

  • Unidentified Participant

    Unidentified Participant

  • Hi. This is [Amitan], on for Mitchell. Thank you for taking our question. And congrats on a strong quarter.

    嗨,我是 [Amitan],代 Mitchell 提問。感謝讓我們提問。也恭喜本季表現強勁。

  • For subcutaneous belantamab, is the Phase 1b study designed primarily to establish PK comparability? Or are you also looking at peak exposure and how that improves safety?

    關於皮下注射 belantamab,第一期 1b 研究主要是為了建立 PK 的可比性嗎?還是你們也在觀察峰值暴露量,以及這如何改善安全性?

  • And I think one thing that we're interested in is: Which toxicities do you believe could improve?

    另外我們也想了解:你們認為哪些毒性可能會改善?

  • And I have a quick follow-up. Thank you.

    我還有一個簡短的追問。謝謝。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yes. I don't believe GSK has posted a lot of details with regard to this study so what I will be able to do is just speak in generalities about where we believe that ENHANZE is going to be able to be impactful with antibody-drug conjugates.

    是的。我認為 GSK 尚未公布太多關於此研究的細節,因此我能做的是以較一般性的方式,談談我們認為 ENHANZE 在抗體藥物複合體(ADC)上可能發揮影響力的方向。

  • And Phase 1 studies often evaluate the pharmacokinetics. And that's exactly what I would expect in this case.

    而第一期研究通常會評估藥物動力學。在這個案例中,我也正是如此預期。

  • And I do believe we'll be looking at the absorption profile, identifying: Is the Cmax coming down with ENHANZE versus, perhaps, what's historically been seen with IV? But, also, what is the overall exposure, which does correlate, generally, very well with efficacy?

    我也相信我們會觀察吸收曲線,確認:相較於過去靜脈注射(IV)的歷史數據,使用 ENHANZE 是否能降低 Cmax。同時也會看整體暴露量,而這通常與療效有非常良好的相關性。

  • So, that, in general terms, is what we would expect for them to be looking at.

    所以,概括來說,這就是我們預期他們會關注的內容。

  • Again, speaking in generalities, we are -- in talking with broad partners, Cmax-related toxicities can be anything from low white-cell counts to [GI] distress to, even, ocular challenges, as well.

    同樣地,泛泛而談,在與廣泛的合作夥伴交流時,與 Cmax 相關的毒性可能涵蓋從白血球計數偏低到腸胃道([GI])不適,甚至也包括眼部方面的問題。

  • So each ADC that we work with is going to be different in terms of what the partner is seeking to mitigate, potentially, with the change in the profile.

    因此,我們合作的每一個 ADC,在合作夥伴希望透過改變該特徵曲線來降低(緩解)的面向上,都會有所不同。

  • Some are very much just focused on, though, getting to an even stronger overall risk-benefit profile, perhaps being able to even dial up the efficacy a bit with a higher exposure.

    有些則非常專注於提升整體風險效益概況,或許甚至能在更高暴露量下把療效再往上調一些。

  • So each partner has got different objectives. And we look forward to GSK sharing their objectives at some later date.

    所以每個合作夥伴都有不同的目標。我們也期待 GSK 在日後某個時間分享他們的目標。

  • Unidentified Participant

    Unidentified Participant

  • Got it. Thank you.

    了解。謝謝。

  • And then, with additional targets being committed to existing partners, what obligations or what are the dynamics acoompanying deadlines accompanying ENHANZE exclusivity? When can Halozyme recover a target, for example, if that partner does not advance it?

    另外,當把額外的標的承諾給既有合作夥伴時,ENHANZE 的獨家權所伴隨的期限,相關義務或運作機制是什麼?例如,如果合作夥伴沒有推進某個標的,Halozyme 何時可以收回該標的?

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. We have been in a very fortunate position that most of our partners, when they take exclusive targets, have advanced them or are advancing them. There have been instances, rarely, over the years, where, perhaps, a product has not progressed in the clinic or had the efficacy that was expected.

    是的。我們很幸運的是,大多數合作夥伴在取得獨家標的後,都已推進或正在推進。多年來也曾有少數情況,例如某個產品在臨床上未能推進,或療效未達預期。

  • And I will say, in those instances, as soon as the company made a decision not to move forward with that target, they have returned it to Halozyme.

    我想說的是,在那些情況下,一旦公司決定不再推進該標的,他們就會把它歸還給 Halozyme。

  • So that is generally the structure of our agreements.

    所以這一般就是我們協議的架構。

  • Unidentified Participant

    Unidentified Participant

  • Got it. Thank you.

    了解。謝謝。

  • Operator

    Operator

  • Sean Laaman, Morgan Stanley.

    Morgan Stanley 的 Sean Laaman。

  • Sean Laaman - Analyst

    Sean Laaman - Analyst

  • Hi, Helen and team. Congratulations on the numbers. And hope everyone's well.

    嗨,Helen 和團隊。恭喜這次的數字表現。也希望大家都一切安好。

  • Helen, on slide 6, when you're talking through those new products, new pipeline products, which are largely in Phase 1, how should we think about those as potential contributors, post the commencement of reduced royalty rates?

    Helen,在第 6 張投影片,當你談到那些新產品、新的管線產品(多數處於第一期)時,我們應該如何看待它們在權利金費率開始下調之後,作為潛在貢獻來源的角色?

  • I assume, some of these partners, the royalty rate reduces, in line with some of your existing marketed products.

    我猜其中一些合作夥伴的權利金費率,會像你們現有的一些已上市產品一樣下調。

  • And then, I have a follow-up.

    然後我還有一個追問。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. The way we think about that portfolio, Sean, is very much one that what's exciting about it is the breadth of products that are in there. There is a mix of already established commercial products. But we're also very proud to be working with partners who are trying to move forward true innovations in care and not just me-toos.

    是的。我們看待那個產品組合的方式,Sean,是它令人興奮之處在於其中產品的廣度。裡面既有已經成熟的商業化產品的組合。但我們也非常自豪能與合作夥伴一起推動真正的照護創新,而不只是 me-too 產品。

  • And so, if we -- on the call, I happened to mention Pfizer's trispecific tilrekimig, which is going to make a big difference, we believe, in patients with type 2 inflammation.

    因此,如果我們——我在電話會議上剛好提到輝瑞的三特異性 tilrekimig,我們相信它將為第二型發炎的患者帶來很大的改變。

  • So think of it as an exciting and broad portfolio.

    所以可以把它視為一個令人興奮且多元的產品組合。

  • The deal structures are all a little bit different in some of our more recent deals. Some of which are represented on that chart.

    交易架構各有些不同;在我們較近期的一些交易中也是如此。其中一些已呈現在那張圖表上。

  • And we have a deal structure where it starts in the low-single-digit royalties, going up into the mid-single-digit royalties. But, in that instance, there is a modest reduction in the royalty rate, if there are no valid patents.

    我們有一種交易架構:權利金從低個位數百分比起步,逐步提高到中個位數百分比。但在那種情況下,如果沒有有效專利,權利金費率會小幅下調。

  • And so it's a very wide range of opportunities. But the message we have is exciting products; big TAM represented by these products; durable royalties, with many of them going into the 2040s, we project; and not all of them having step-downs, depending on if they get co-form patents, which we believe many of them will get.

    因此機會範圍非常廣。但我們要傳達的訊息是:產品令人興奮;這些產品代表很大的 TAM(總可服務市場);權利金具持久性——我們預期其中許多可延續到 2040 年代;而且並非所有產品都有階梯式下調,取決於它們是否取得共同配方(co-form)專利,而我們相信其中許多會取得。

  • This is why we talk about the great value of our compounding platform engine because we're able to just keep adding wave upon wave of attractive royalties.

    這也是為什麼我們談到我們複利式平台引擎的巨大價值,因為我們能一波接一波地持續加入具吸引力的權利金來源。

  • Sean Laaman - Analyst

    Sean Laaman - Analyst

  • Interesting. Thank you.

    很有意思。謝謝。

  • And I have a question on KEYTRUDA QLEX. According to the FDA approval letter for KEYTRUDA QLEX, the finished product is manufactured and filled by -- I think it's BSP Pharmaceuticals in Italy, which appears to be the only FDA-approved facility for this purpose.

    我還有一個關於 KEYTRUDA QLEX 的問題。根據 FDA 對 KEYTRUDA QLEX 的核准信,成品是由——我想是義大利的 BSP Pharmaceuticals——製造並充填,而這似乎是唯一獲 FDA 核准可用於此目的的設施。

  • I think the October 7 Dutch injunction prohibits Merck's Dutch subsidiary from manufacturing or arranging manufacturing in the affected countries, as well as facilitating infringement by its affiliates.

    我認為 10 月 7 日的荷蘭禁制令,禁止默克的荷蘭子公司在受影響國家製造或安排製造,並且也禁止其協助關係企業的侵權行為。

  • I'm just wondering, the injunction does not appear to distinguish between manufacturing for sale in those countries and manufacturing for export elsewhere. Would it be right to potentially assume that it affects Merck's ability to supply QLEX to the US and other markets outside the scope of the injunction?

    我想確認的是,該禁制令看起來並未區分是為在那些國家銷售而製造,或是為出口到其他地方而製造。是否可以合理推測,這會影響默克向美國及其他不在禁制令範圍內的市場供應 QLEX 的能力?

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. We can't address the potential impact on US supply, as we don't have full knowledge of Merck's worldwide supply chain.

    是的。我們無法評論對美國供應的潛在影響,因為我們並不完全掌握默克的全球供應鏈。

  • But let me just take a step back and talk about what the Dutch court prohibited, just to provide a little bit of context, and tell you where the prohibition is.

    但我先退一步,說明荷蘭法院禁止了什麼,以提供一些背景,並告訴你禁令的範圍所在。

  • So the ruling from the Dutch court did stop Merck's EMA holder and its affiliates from committing an infringement in multiple European countries, as you know, including, though, by the manufacturer or causing KEYTRUDA QLEX to be manufactured in those countries.

    因此,荷蘭法院的裁定確實禁止默克的 EMA 持有人及其關係企業在多個歐洲國家實施侵權行為,如你所知,其中也包括由其在那些國家製造或促使 KEYTRUDA QLEX 在那些國家被製造。

  • As you mentioned, we know that BSP Pharmaceuticals in Italy is a manufacturer for QLEX for Merck. The current prohibition by the court that's in place for Merck's EMA holder and its affiliates, we believe, does impact those entities' ability to supply QLEX from BSP entity, regardless of the ultimate destination of the product.

    如你所提到,我們知道義大利的 BSP Pharmaceuticals 是默克 QLEX 的製造商之一。法院目前對默克 EMA 持有人及其關係企業所施行的禁令,我們認為,確實會影響這些實體從 BSP 供應 QLEX 的能力,而不論產品最終目的地為何。

  • And that's an important distinction there. I will say Halozyme has also taken some additional actions and has sued BSP directly for infringement of EP622.

    這是一個重要的區別。我也要補充,Halozyme 也採取了額外行動,並已直接對 BSP 提起訴訟,主張其侵害 EP622。

  • So it's clear around the EMA holder, its affiliates, and what we know about BSP Pharmaceuticals; cannot comment on US supply.

    因此,關於 EMA 持有人、其關係企業,以及我們對 BSP Pharmaceuticals 的了解,情況是清楚的;但無法評論美國供應。

  • Sean Laaman - Analyst

    Sean Laaman - Analyst

  • Got you. Extremely helpful on both questions. I appreciate it.

    了解。兩個問題的回答都非常有幫助。感謝。

  • Operator

    Operator

  • Dave Risinger, Leerink Partners.

    Leerink Partners 的 Dave Risinger。

  • David Risinger - Analyst

    David Risinger - Analyst

  • Sorry about that. Thanks very much for all the updates today. And nice to see the progress.

    抱歉剛剛那樣。非常感謝今天提供的所有更新。也很高興看到進展。

  • I wanted to start on Hypercon. So, Helen, could you just comment on whether there's any change today in the expected timing of two potential Phase-1 starts in 2027?

    我想先從 Hypercon 談起。所以,Helen,你能否評論一下,今天對於 2027 年兩個可能啟動第一期試驗的預期時程,是否有任何變化?

  • I think you mentioned, the first half of '27. I do not know if both were previously expected to start in the first half. I just cannot recall.

    我想你提到是 2027 年上半年。我不確定先前是否預期兩個都會在上半年啟動。我只是記不太清楚。

  • And then, second, with respect to -- so one other Hypercon question; and then, I have one more, please.

    然後第二個,關於——還有一個 Hypercon 的問題;之後我還有一題,謝謝。

  • So the second Hypercon question is: Could you talk about scale-up? I know that it has been somewhat challenging to scale up Hypercon. Could you address that, please? Thank you.

    第二個 Hypercon 問題是:能否談談放大生產(scale-up)?我知道 Hypercon 的放大生產一直有些挑戰。能否請你說明一下?謝謝。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. Dave, there is no change, recently, in our timeline of the expectation of when we would have the first clinical starts. Much earlier this year, we had stated that we expected, now, that the first clinical starts would be in the first half of 2027. And that is where we are tracking.

    是的,Dave,我們近期對於首次臨床啟動時間的預期時程沒有改變。在今年更早的時候,我們已表示我們現在預期首次臨床啟動會在 2027 年上半年。目前進度就是依此在推進。

  • And, I mentioned on the call, we are expecting to make our first clinical supplies for the first two partners in the first quarter to support the starts during the first half of 2027.

    而且我在電話會議上也提到,我們預期會在第一季為前兩個合作夥伴製作第一批臨床供應品,以支援 2027 年上半年的啟動。

  • With regard to the scale-up, any novel project like this does come with the need to evolve it, as you are going on. And, I have to say, we have been making very, very strong progress with that. And that is what gives me confidence in supply.

    關於放大規模(scale-up),像這樣任何新穎的專案,在推進過程中都確實需要持續演進。而且我必須說,我們在這方面已經取得非常、非常強勁的進展。這也是讓我對供應有信心的原因。

  • So the team has done a super job, going from bench scale into now being just quarter and a bit away from the actual scale-up to clinical supply. And, obviously, that was incredibly important as a Milestone for us to be able to support the new clinical starts.

    所以團隊做得非常出色,從實驗室規模一路推進到現在,距離實際放大到臨床供應只差大約四分之一多一點的路程。而且很明顯,這對我們而言是一個極其重要的里程碑,使我們能夠支持新的臨床啟動。

  • And, once we have done that, we have to start thinking about commercial launch and commercial supply. And so that is where we are very, very hard at work, at the moment, finding additional partners to be able to do that process.

    而一旦完成這一步,我們就必須開始思考商業上市與商業供應。因此,我們目前正非常、非常努力地尋找額外的合作夥伴,以便能夠完成該流程。

  • But we expect that to be a very straightforward process because the hard work happens between your bench and your first clinical scale-up because all that the commercial scale-up will be will be a slightly bigger volume but it will use, largely, the identical process.

    但我們預期這會是一個非常直接的流程,因為最艱難的工作發生在實驗室到首次臨床放大之間;商業化放大所需做的,只是稍微更大的產量,但大體上會使用幾乎相同的製程。

  • Really pleased with the progress and success that we are having there and look forward to keeping you updated.

    我們對目前取得的進展與成功感到非常滿意,也期待持續向各位更新。

  • David Risinger - Analyst

    David Risinger - Analyst

  • Great. Thank you.

    很好。謝謝。

  • And then, the other one relates to the Merck litigation. So I think many observers have been surprised that Merck hasn't settled with Halozyme to be able to introduce its SUBCUTANEOUS KEYTRUDA in Europe.

    另外一個問題與默克(Merck)的訴訟有關。我想許多觀察者都很驚訝,默克尚未與 Halozyme 和解,以便能在歐洲推出其皮下(SUBCUTANEOUS)KEYTRUDA。

  • Yeah. I'm guessing that if the company is having conversations with Merck, that it may relate to not just European litigation but also US litigation.

    是的。我猜如果公司正在與默克對話,可能不僅與歐洲訴訟有關,也可能與美國訴訟有關。

  • So my two questions are: First, could you compare and contrast your success in Europe versus your lack of success, to date, in the US; and comment specifically on that patent that blocked Merck in Europe?

    所以我有兩個問題:第一,您能否比較並對照你們在歐洲的成功與迄今在美國的未成功;並特別評論那件在歐洲阻擋默克的專利?

  • And then, second, where are you, with respect to having conversations with Merck?

    第二,就與默克進行對話而言,你們目前進展到哪一步?

  • Thanks very much.

    非常感謝。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. I'll take the second part first, David. We haven't engaged in any conversations with Merck. And, obviously, if we did do that, we wouldn't be in a position to provide any updates on that.

    好的,David,我先回答第二部分。我們沒有與默克進行任何對話。而且很明顯,即使我們有進行,我們也不會處於可以提供任何更新的立場。

  • But let's talk about where we are in Europe. We're absolutely thrilled with the resounding win from the Dutch court, which not only found that Merck was infringing -- and this was a final decision after a full trial.

    但我們來談談我們在歐洲的情況。我們對荷蘭法院壓倒性的勝訴感到非常振奮;該法院不僅認定默克構成侵權——而且這是在完整審理後作出的終局判決。

  • They were found to be infringing on October 17. And, importantly, the court also said, at that time, that there's no reasonable likelihood that EP622, which is that key European patent, will be declared invalid in any other relevant European member states, where EP622 is granted.

    他們在 10 月 17 日被認定侵權。而且重要的是,法院當時也表示,沒有合理可能性會在其他相關的歐洲成員國(EP622 已獲核准的國家)宣告 EP622(那件關鍵的歐洲專利)無效。

  • Now, why do I emphasize that? I emphasize that because that really supported the court's decision to have this broad restriction from launching in eight of the European markets.

    那麼,我為什麼要強調這一點?我強調是因為這確實支持了法院作出廣泛限制、禁止其在八個歐洲市場上市的決定。

  • And, as you know, we already have an injunction in Germany, as well.

    而且如你所知,我們在德國也已經取得禁制令。

  • The European (inaudible) -- this EP622 is distinct from the US -patent portfolio. And we're very pleased with the recognition by the European -- and, particularly, the Dutch and German patent courts -- on the validity of our patent and the fact that we are being infringed.

    歐洲(聽不清)——這件 EP622 與美國的專利組合不同。我們對歐洲——尤其是荷蘭與德國專利法院——對我們專利有效性的認可,以及對我們遭到侵權這一事實的認定,感到非常滿意。

  • And it's important because, as we look at Europe, those eight markets and nine markets, including Germany, in our experience from the subcu market, represent about 20% of total global royalties.

    這很重要,因為就歐洲而言,這八個市場以及加上德國的九個市場,依我們在皮下市場(subcu market)的經驗,約占全球權利金總額的 20%。

  • So we think this was a very important win, strategically, for Halozyme.

    因此,我們認為這在策略上是 Halozyme 一場非常重要的勝利。

  • And, if we move to the US, to date, yes, Merck has been successful in gaining initial rulings on our US patents, which, as I say, are distinct. And we've received adverse validity decisions on multiple of our PGRs that were filed.

    如果轉到美國,迄今為止,是的,默克在我們的美國專利上取得了初步裁定的勝利;如我所說,這些專利是不同的。而且我們在已提出的多件 PGR 上收到了不利的有效性決定。

  • However, we are very confident that, as we move forward into an appeal process here, which will take likely until 2028, that we will prevail. There's a lot of facts behind that statement, Dave, but it really comes from us being the pioneer in this area. And we believe that the appeal court will recognize just how strong our case is in terms of that.

    然而,我們非常有信心,隨著我們在此進入上訴程序——可能要到 2028 年——我們將會勝出。Dave,這個判斷背後有很多事實,但主要源於我們是這個領域的先驅。我們相信上訴法院會認可我們在這方面的案情有多強。

  • So very different patent systems, different patents in each of these. We do expect, over time, we're going to reap the same success in the US, as we have seen in Europe, to date.

    所以,專利制度不同、各自的專利也不同。我們確實預期,隨著時間推進,我們在美國也會收穫與迄今在歐洲所見相同的成功。

  • David Risinger - Analyst

    David Risinger - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Brendan Wiatrowski, TD Cowen.

    Brendan Wiatrowski,TD Cowen。

  • Brendan Smith - Analyst

    Brendan Smith - Analyst

  • Hi, guys. I think that is supposed to be me, Brendan Smith. Sorry for the confusion there. Thanks for taking the questions.

    嗨,各位。我想應該是我,Brendan Smith。抱歉造成混淆。謝謝讓我提問。

  • Appreciate all the color on, especially the progress, the next wave of ENHANZE assets. And I did notice higher bulk API sales for the ENHANZE enzyme, itself, this quarter, which, presumably, will continue to ramp, as more drugs move through the clinic this and next year.

    很感謝你們提供的各種細節,特別是關於下一波 ENHANZE 資產的進展。我也注意到本季 ENHANZE 酵素本身的散裝 API 銷售較高;推測隨著更多藥物在今年與明年進入並推進臨床,這應會持續爬升。

  • Helen, can you just remind us, how should we think about the comparable revenue contribution from Hypercon, as those assets move into and through the clinic? I think it is more Milestone-based, rather than API sales. But how material could those be next year, as the first couple Hypercon drugs start Phase 1?

    Helen,你能否提醒我們,當這些資產進入並推進臨床時,我們應該如何看待 Hypercon 在可比口徑下的營收貢獻?我認為它比較偏向里程碑(Milestone)為主,而不是 API 銷售。但明年第一、第二個 Hypercon 藥物開始第一期(Phase 1)時,這些可能有多大程度的貢獻?

  • And, just secondly, related to that, are there any updates on when you might expect the third and fourth Hypercon drugs to enter the clinic, after those first two start, on the first half of next year? Thanks.

    另外第二點也相關:在明年上半年前兩個先啟動之後,第三與第四個 Hypercon 藥物預計何時可能進入臨床?有任何更新嗎?謝謝。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. You are quite right, Brendan, that, for Hypercon, we will not be seeing [API] revenue. We'll see a small amount of Collaboration revenue, as we do experiments and partners pay for that work and our [FTEs]. But it's not the same model, in terms of the API, so don't expect a line in API.

    是的,Brendan,你說得完全正確,Hypercon 不會有 [API] 營收。我們會看到少量的合作收入(Collaboration revenue),因為我們會做實驗,而合作夥伴會為那部分工作與我們的 [FTEs] 付費。但就 API 而言,模式不同,所以不要期待在 API 那一行看到收入。

  • But the model is very similar to our ENHANZE profile that you've seen for the 10 approved products, where as a product is progressing to become more and more de-risked, there are escalating Milestones.

    但其模式與你在我們 10 個已核准產品上看到的 ENHANZE 概況非常相似:隨著產品推進、風險逐步降低,里程碑款會逐級提高。

  • So Phase 3 is usually substantially higher than a Phase 1 Milestone. There are meaningful Milestones at approval. And then, Milestones as products, achieve certain sales thresholds.

    因此,第三期(Phase 3)的里程碑通常會顯著高於第一期(Phase 1)的里程碑。在核准時也會有具意義的里程碑款。之後,當產品達到特定銷售門檻時,也會有里程碑款。

  • So very similar. And it can, you are quite right, be a meaningful contributor to our Milestone revenue over time.

    所以非常相似。而且你說得沒錯,隨著時間推進,它確實可以對我們的里程碑收入做出有意義的貢獻。

  • With regard to products 3 and 4, I mentioned that we are very pleased with the progress we're seeing and how broad the development pipeline is. We don't have specific dates from those partners, as to when they will be moving into the clinic.

    至於第 3 與第 4 個產品,我提到我們對目前看到的進展以及開發管線的廣度感到非常滿意。但我們尚未從那些合作夥伴取得具體日期,說明他們何時會推進到臨床。

  • But we can say numbers 3 and 4 are getting teed up. And we'll look forward to providing an update, when those clinical-start dates are more clear to us.

    但我們可以說,第 3 與第 4 個正在準備就緒。等到那些臨床啟動日期對我們更明確時,我們也期待能提供更新。

  • Brendan Smith - Analyst

    Brendan Smith - Analyst

  • Great. Thanks.

    很好。謝謝。

  • And then, if I could just quickly follow up: I know you've, in the past, I think, flagged, I think, 13 new launches between 2029 and 2031. Can you, first, confirm if that's still what we should expect in terms of the number and timing of that next wave?

    然後,如果我可以再快速追問:我知道你們過去曾經(我想)提到在 2029 到 2031 年之間有 13 個新上市。你們能否先確認,就下一波的數量與時程而言,我們仍應該這樣預期嗎?

  • But then, also, if the 13 ENHANZEs you're flagging here in the deck are to be in the clinic by the end of this year, are those the same 13 or if there's any other, maybe, new indications or Hypercon, included, in that 2029 to '31 timeframe? Thanks.

    不過另外,如果你們在簡報中標示的這 13 個 ENHANZE 計畫都會在今年底前進入臨床,那麼在 2029 到 '31 的時間範圍內,會是同樣的 13 個嗎?還是會包含其他可能的新適應症或 Hypercon?謝謝。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. The 13 products are all new molecular entities in terms of what we count. We actually will have other new indications launching, Brendan, particularly, as an example, on VYVGART that continues to just add and expand.

    是的。我們所說的 13 個產品,就我們的計算方式而言,全部都是新分子實體(NME)。實際上我們也會有其他新適應症上市,Brendan,例如 VYVGART 會持續新增並擴展。

  • Those aren't on the list so that is not considered. This is actual new products moving into the clinic.

    那些不在清單上,因此不算在內。這裡指的是實際的新產品進入臨床。

  • We have said, yes, up to 13 of these will launch between 2029 and, I do believe it was more, 2032. But it is going to be in that window, if they follow -- and we would expect them to -- our usual timeline for development, which is anything from 4.5 to 5.5 years.

    我們確實說過,是的,最多 13 個會在 2029 年到——我記得是更晚一些——2032 年之間上市。但會落在那個時間窗內,前提是它們遵循——而我們也預期會——我們一貫的開發時程,也就是大約 4.5 到 5.5 年。

  • So that's what's giving us that confidence in that window.

    所以這就是我們對那個時間窗有信心的原因。

  • Now, obviously, they have to advance in development. But up to 13 is exactly the number.

    當然,它們必須在開發上持續推進。但「最多 13 個」這個數字就是確切的數量。

  • Brendan Smith - Analyst

    Brendan Smith - Analyst

  • Got it. Sounds good. Thank you.

    了解。聽起來很好。謝謝。

  • Operator

    Operator

  • Jessica Fye, JP Morgan.

    Jessica Fye,摩根大通。

  • Jessica Fye - Analyst

    Jessica Fye - Analyst

  • Hey, guys. Good afternoon. Thanks for taking my question.

    嗨,各位。下午好。謝謝讓我提問。

  • Maybe, coming back to Hypercon, just to -- you've mentioned for a couple quarters now that a Hypercon partner is evaluating the potential return of a target. Just talk us through what are various reasons that partners return targets?

    也許回到 Hypercon 的話題,想請教——你們已經連續幾個季度提到,有一位 Hypercon 合作夥伴正在評估某個標的可能被退回的情況。能否談談合作夥伴退回標的的各種原因?

  • And then, the second one is: What's the viscosity that you're seeing with the Hypercon-formulated products? This may just vary by product. But is there any upper bound that you want to stay under? And are you finding that you're able to do that, thus far?

    第二個問題是:你們在 Hypercon 配方產品上看到的黏度是多少?這可能會因產品而異。但你們是否有希望維持在某個上限以下?到目前為止,你們是否發現能做到?

  • Thank you.

    謝謝。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • Yeah. With regard to -- Jess, I'll talk broadly on this, as to why a partner might choose to return a target. It could be that they may have decided not to develop that product. That's the most common reason. And I talked about that a little bit earlier -- that that's happened over the years with ENHANZE.

    好的。關於——Jess,我會用較概括的方式來談,合作夥伴為什麼可能選擇退回一個標的。可能是他們決定不再開發那個產品。這是最常見的原因。我先前也稍微提到過——多年來 ENHANZE 也發生過這種情況。

  • With regard to the specific statement on Hypercon, we really can't say any more about that. That program is actually progressing. And so we can't say more about that at this period of time.

    至於你提到 Hypercon 的那個具體說法,我們目前真的無法再多說。那個計畫其實正在推進中。因此在這個時間點我們不能透露更多。

  • But, generally, it is, if a product doesn't progress in the clinic or didn't achieve the efficacy profile that a partner would want.

    但一般而言,如果產品在臨床上沒有進展,或沒有達到合作夥伴想要的療效特徵,就可能會被退回。

  • And you may remember, with our Bristol agreement, some of the earlier immunology, immune-oncology, targets that were more novel did not actually meet the clinical expectations. And so BMS returned those targets, when that was determined. So that is the most common reason that we see.

    你可能還記得,在我們與 Bristol 的協議中,一些較早期、較新穎的免疫學與免疫腫瘤標的,實際上沒有達到臨床預期。因此在確認後,BMS 就退回了那些標的。所以這是我們最常見看到的原因。

  • The Hypercon team do not talk in terms of viscosity. But, basically, what I can say is, we seek to have the injection strength be, perhaps, in the 40 to 50 newtons, which is the hand grip of a small child, as an example.

    Hypercon 團隊不會用黏度來表述。但基本上我可以說的是,我們希望注射所需的力量大概在 40 到 50 牛頓左右,舉例來說,這大約相當於小孩的手握力。

  • Many of our drugs -- that is easily injectable by an adult, as you can imagine. But many of the drugs in Hypercon, we expect to be actually being given by auto-injector, which, obviously, can exert -- and, certainly, the Halozyme auto-injectors have a lot more force that they can inject than that.

    我們許多藥物——如你所想,成人都能很容易注射。但 Hypercon 中的許多藥物,我們預期實際上會透過自動注射器給藥;而自動注射器顯然可以施加——而且 Halozyme 的自動注射器確實能施加遠高於此的注射力量。

  • So what is remarkable about the Hypercon formulation is for the concentration, the ease with which it can be injected.

    因此 Hypercon 配方令人驚豔之處在於:在這樣的濃度下,仍然能夠很容易注射。

  • Operator

    Operator

  • Mohit Bansal, Wells Fargo.

    Mohit Bansal,富國銀行。

  • Unidentified Participant 2

    Unidentified Participant 2

  • Hi. This is [Yanan Zhu], on from Mohit. Thanks for taking our question. And congrats on the quarter.

    嗨,我是 [Yanan Zhu],代 Mohit 發言。謝謝讓我們提問。也恭喜本季表現。

  • I just have one question regarding 2027 and beyond: Shall we expect an update on the multi-year outlook in early next year, as typical?

    我只有一個關於 2027 年及之後的問題:我們是否可以像往常一樣,預期你們在明年初更新多年期展望?

  • And then, I think you guys previously mentioned that the new three launches for ENHANZE, like, together contribute around 80% -- sorry -- grow about 80% sequentially in the second quarter.

    另外,我記得你們之前提到 ENHANZE 的三個新上市產品合計在第二季季比大約成長 80%——抱歉——大約季增 80%。

  • Just curious how much of that potential thousand (inaudible) -- royalty step-down between 2029 and '30 could be offset by these new launches?

    想請教在 2029 到 '30 年之間,可能出現的那個(聽不清)——權利金下調(step-down)有多少能被這些新上市所抵銷?

  • And then, I have a follow-up question. Thank you.

    另外我還有一個追問。謝謝。

  • Darren Snellgrove - Chief Financial Officer

    Darren Snellgrove - Chief Financial Officer

  • Yeah. Thanks for the question.

    好的,謝謝你的問題。

  • So we do plan to give 2027 guidance and an update on our long-range outlook, when we report fourth-quarter results in February. And we remain very comfortable with the outlook and look forward to providing the update.

    我們確實計畫在 2 月公布第四季財報時,提供 2027 年指引並更新我們的長期展望。我們對展望仍然非常有信心,也期待屆時提供更新。

  • Helen Torley - President, Chief Executive Officer, Director

    Helen Torley - President, Chief Executive Officer, Director

  • I think on the quarter-over-quarter growth and talking about the exciting new waves that we're seeing, we continue to see strong growth in those products.

    至於季對季成長,以及我們看到令人振奮的新一波動能,我們持續看到這些產品的強勁成長。

  • And, for each of those, there's a lot of growth left. I highlighted some of it in my call. But, just to mention, OPDIVO QVANTIG is about 17% converted today. Bristol expects it to be to 30% to 40% over the next several years. And, for that to continue, as we have seen -- that moving to subcu is very sticky in terms of share.

    而且對每一個產品來說,後續仍有很大的成長空間。我在電話會議中也強調了一些。不過簡單提一下,OPDIVO QVANTIG 目前大約轉換了 17%。Bristol 預期未來幾年會提升到 30% 到 40%。而且如我們所見——轉到皮下(subcu)在市占上非常黏著(sticky)。

  • For OCREVUS ZUNOVO, that's just at about 20% conversion today of what will be an $11 billion at-market so very exciting there, as well.

    至於 OCREVUS ZUNOVO,目前轉換率大約 20%;而其市場規模將達到 110 億美元,因此也非常令人振奮。

  • And then, RYBREVANT SUBCU, annualizing, out to about $1.3 billion but J&J has projected, at least, $5 billion in shares there.

    再來是 RYBREVANT SUBCU,按年化推算約 13 億美元,但嬌生(J&J)至少預測那裡的市占可達 50 億美元。

  • So you're quite right in focusing on these being very meaningful contributors. But that's all the detail we can give you today.

    所以你把焦點放在這些產品會成為非常重要的貢獻者,是完全正確的。但今天我們能提供的細節就到這裡。

  • Unidentified Participant

    Unidentified Participant

  • Thank you. And I just have another question regarding the Collaboration revenues. I think you guys maintained the full-year guidance of $110 million to $130 million versus -- roughly, about $65 million, so far, has been kicked in.

    謝謝。我還有另一個關於合作收入(Collaboration revenues) 的問題。我看到你們維持全年指引在 1.10 億到 1.30 億美元;相較之下——目前大約已認列了 6,500 萬美元左右。

  • So shall we still expect the remaining revenue to be recognized in the fourth quarter? Or has some of the portion of it will be shifted to 2027?

    那我們是否仍可預期剩餘收入會在第四季認列?還是其中一部分會延後到 2027 年?

  • Darren Snellgrove - Chief Financial Officer

    Darren Snellgrove - Chief Financial Officer

  • Always hard to predict exactly how the Collaboration revenue is going to pan out. But we did guide to expect a little bit heavier weighting of that in the fourth quarter.

    合作收入的實際走勢一向很難精準預測。但我們確實在指引中提到,預期第四季的比重會稍微高一些。

  • So I think you can expect to see some more coming in in fourth quarter.

    所以我想你可以預期第四季會再進來一些。

  • Unidentified Participant

    Unidentified Participant

  • Got it. Thank you.

    了解。謝謝。

  • Operator

    Operator

  • We have reached the end of the Q&A session, which concludes today's call.

    我們已到問答環節結束,今天的電話會議到此結束。

  • Thank you so much for attending. You may now disconnect.

    非常感謝各位參與。您現在可以斷線。